The dapagliflozin action is to prevent the reabsorption of glucose by stimulating the kidneys and expelled through the urine so as to reduce high glucose levels.

A new drug for patients with type 2 diabetics is not insulin improves control of blood glucose and helps you lose weight, according to a study published today in The Lancet.

The drug, dapagliglozin could be considered as a new therapeutic option for patients who fail to match their blood glucose levels with the traditional treatment with metformin and those leading or trailing in states of diabetes.

The dapagliflozina acts to prevent the reabsorption of glucose by stimulating the kidneys and expelled through the urine so as to reduce high levels of blood glucose (hyperglycemia) without affecting insulin-dependent systems.

A group of researchers from the University Of Aston (UK) demonstrated the efficacy and safety of the dapagliflozina in patients unable to control their glucose levels with metformin -based therapy.

“The substance is independent of insulin, low weight and is not associated with risk of hypoglycemia. In addition, we have demonstrated the safety and tolerability of treatment, “concluded the authors of the research for those who can become dapagliflozina an alternative treatment for type 2 diabetes.